Table 2. Site-specific risk of second primary malignancy following CLL.
|
Men
|
Women
|
Total
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Second cancer site (ICD-10) | O | SIR | 95% CI | O | SIR | 95% CI | O | SIR | 95% CI |
| Lip (C00) | 33 | 6.26 | 4.31, 8.79 | 12 | 6.80 | 3.51, 11.9 | 45 | 7.17 | 5.23, 9.60 |
| Oral cavity and pharynx (C01–C14) | 29 | 2.30 | 1.54, 3.30 | 6 | 1.46 | 0.54, 3.17 | 35 | 2.33 | 1.63, 3.25 |
| Oesophagus (C15) | 12 | 1.05 | 0.54, 1.83 | 9 | 1.65 | 0.76, 3.14 | 21 | 1.34 | 0.83, 2.05 |
| Stomach (C16) | 28 | 1.20 | 0.80, 1.74 | 7 | 0.74 | 0.30, 1.52 | 35 | 1.17 | 0.81, 1.62 |
| Colorectal (C18–C20; C218) | 146 | 1.82 | 1.54, 2.14 | 101 | 2.02 | 1.64, 2.45 | 247 | 1.98 | 1.74, 2.25 |
| Liver (C22) | 9 | 1.14 | 0.52, 2.16 | 0 | — | — | 9 | 0.97 | 0.44, 1.84 |
| Gallbladder (C23–C24) | 7 | 1.48 | 0.59, 3.05 | 6 | 1.19 | 0.44, 2.58 | 13 | 1.31 | 0.70, 2.24 |
| Pancreas (C25) | 21 | 1.17 | 0.72, 1.79 | 14 | 1.00 | 0.55, 1.68 | 35 | 1.12 | 0.78, 1.56 |
| Larynx (C32) | 13 | 2.01 | 1.07, 3.44 | 0 | — | — | 13 | 2.25 | 1.20, 3.85 |
| Lung (C33–C34) | 216 | 1.98 | 1.72, 2.26 | 59 | 1.86 | 1.41, 2.40 | 275 | 2.17 | 1.93, 2.45 |
| Melanoma (C44; M872–M879) | 201 | 7.40 | 6.42, 8.50 | 71 | 6.40 | 5.00, 8.07 | 272 | 7.74 | 6.85, 8.72 |
| Connective tissue and peripheral nerves (C47, C49) | 13 | 5.71 | 3.04, 9.77 | 4 | 3.26 | 0.89, 8.35 | 17 | 5.13 | 2.99, 8.21 |
| Female breast (C50) | — | — | — | 86 | 1.93 | 1.55, 2.39 | 86 | 1.93 | 1.55, 2.39 |
| Uterine corpus (C54) | — | — | — | 26 | 3.51 | 2.29, 5.15 | 26 | 3.51 | 2.29, 5.15 |
| Ovary (C56) | — | — | — | 15 | 1.52 | 0.85, 2.51 | 15 | 1.52 | 0.85, 2.51 |
| Prostate (C61) | 268 | 1.94 | 1.71, 2.18 | — | — | — | 268 | 1.94 | 1.71, 2.18 |
| Kidney (C64–C66, C68) | 42 | 2.93 | 2.11, 3.96 | 11 | 1.50 | 0.75, 2.69 | 53 | 2.60 | 1.95, 3.40 |
| Bladder (C67) | 58 | 2.21 | 1.68, 2.85 | 13 | 1.87 | 0.99, 3.20 | 71 | 2.42 | 1.89, 3.05 |
| Eye (C69) | 9 | 8.55 | 3.91, 16.2 | 0 | — | — | 9 | 5.98 | 2.73, 11.4 |
| Brain (C71–72) | 10 | 1.16 | 0.56, 2.13 | 9 | 1.87 | 0.85, 3.55 | 19 | 1.47 | 0.89, 2.30 |
| Thyroid (C73) | 3 | 2.87 | 0.59, 8.37 | 6 | 4.96 | 1.82, 10.8 | 9 | 3.89 | 1.78, 7.38 |
| Non-Hodgkin's lymphoma (M967–M972) | 3 | 0.22 | 0.05, 0.65 | 3 | 0.35 | 0.07, 1.03 | 6 | 0.28 | 0.10, 0.62 |
| Hodgkin's disease (M965–M966) | 7 | 7.59 | 3.05, 15.7 | 4 | 7.59 | 2.07, 19.4 | 11 | 7.98 | 3.98, 14.3 |
| Myeloid leukaemia (M984–M993) | 3 | 0.34 | 0.07, 1.01 | 2 | 0.43 | 0.05, 1.54 | 5 | 0.40 | 0.13, 0.92 |
| All LHNs (C81–C96) | 15 | 0.31 | 0.17, 0.51 | 11 | 0.38 | 0.19, 0.68 | 26 | 0.35 | 0.23, 0.51 |
| All malignant neoplasms (C00–C80) | 1265 | 2.12 | 2.00, 2.24 | 528 | 1.84 | 1.69, 2.01 | 1793 | 2.17 | 2.07, 2.27 |
Abbreviations: CI=confidence interval; CLL=chronic lymphocytic leukaemia; ICD=International Classification of Diseases; LHN=lymphohematopoietic neoplasm; O=observed number of cases; SIR=standardised incidence ratio.
Values in bold=95% CI did not include 1.00.